Oral administration of Domain-I of beta-2glycoprotein-I induces immunological tolerance in experimental murine antiphospholipid syndrome

Keyphrases

• Oral Administration 100%
• Antiphospholipid Syndrome 100%
• Immunological Tolerance 100%
• Oral Tolerance 28%
• Interleukin-10 14%
• Inflammatory Response 14%
• Mouse Model 14%
• Interleukin-6 14%
• Inflammatory Cytokines 14%
• Humoral Immunity 14%
• Disease Pathogenesis 14%
• Quantitative PCR 14%
• Anti-inflammatory Response 14%
• Autoantibodies 14%
• Novel Therapies 14%
• Decreased Expression 14%
• New Therapeutic Approaches 14%
• Anti-inflammatory Cytokines 14%
• Immunomodulation 14%
• Interleukin-17 (IL-17) 14%
• Intolerance 14%
• Splenocytes 14%
• Thrombus 14%
• Orally Administered 14%
• Immune Signaling 14%
• Fetal Loss 14%
• Tolerogenic Dendritic Cells 14%
• Tolerance Induction 14%
• I-domain 14%
• Circulating microRNA 14%

INIS

• mice 100%
• oral administration 100%
• tolerance 100%
• inflammation 57%
• proteins 28%
• molecules 28%
• cytokines 28%
• production 14%
• patients 14%
• diseases 14%
• pathogenesis 14%
• pcr 14%
• losses 14%
• size 14%
• comparative evaluations 14%
• induction 14%
• therapy 14%
• immunity 14%
• variations 14%
• dendrites 14%
• lead sulfides 14%

Immunology and Microbiology

• Antiphospholipid Syndrome 100%
• Immune Tolerance 100%
• Mouse 71%
• Molecule 28%
• Inflammation Response 28%
• Inflammatory Cytokine 28%
• Mouse Model 14%
• Interleukin-6 14%
• Humoral Immunity 14%
• Autoantibodies 14%
• Dendritic Cell 14%
• Reverse Transcription Polymerase Chain Reaction 14%
• Bagg Albino Mouse 14%
• Immunomodulation 14%
• Interleukin 17 14%
• Splenocyte 14%